BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32542357)

  • 1. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.
    Norona J; Apostolova P; Schmidt D; Ihlemann R; Reischmann N; Taylor G; Köhler N; de Heer J; Heeg S; Andrieux G; Siranosian BA; Schmitt-Graeff A; Pfeifer D; Catalano A; Frew IJ; Proietti M; Grimbacher B; Bulashevska A; Bhatt AS; Brummer T; Clauditz T; Zabelina T; Kroeger N; Blazar BR; Boerries M; Ayuk F; Zeiser R
    Blood; 2020 Sep; 136(12):1442-1455. PubMed ID: 32542357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2.
    Zeiser R; Chen YB; Youssef NN; Ayuk F
    Br J Haematol; 2023 May; 201(4):620-627. PubMed ID: 36965050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.
    Chopra M; Brandl A; Siegmund D; Mottok A; Schäfer V; Biehl M; Kraus S; Bäuerlein CA; Ritz M; Mattenheimer K; Schwinn S; Seher A; Grabinger T; Einsele H; Rosenwald A; Brunner T; Beilhack A; Wajant H
    Blood; 2015 Jul; 126(4):437-44. PubMed ID: 26012567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
    Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
    Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults.
    Ramos KN; Leino D; Luebbering N; Grimley MS; Badia P; Davies SM; Khandelwal P
    Transplant Cell Ther; 2024 Apr; 30(4):454.e1-454.e6. PubMed ID: 38311212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased secretion of Paneth cell α-defensins in graft-versus-host disease.
    Eriguchi Y; Nakamura K; Hashimoto D; Shimoda S; Shimono N; Akashi K; Ayabe T; Teshima T
    Transpl Infect Dis; 2015 Oct; 17(5):702-6. PubMed ID: 26198302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease.
    Zhao D; Kim YH; Jeong S; Greenson JK; Chaudhry MS; Hoepting M; Anderson ER; van den Brink MR; Peled JU; Gomes AL; Slingerland AE; Donovan MJ; Harris AC; Levine JE; Ozbek U; Hooper LV; Stappenbeck TS; Ver Heul A; Liu TC; Reddy P; Ferrara JL
    J Clin Invest; 2018 Nov; 128(11):4970-4979. PubMed ID: 30106382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Insights Into the Mechanism of GVHD-Induced Tissue Damage.
    Ara T; Hashimoto D
    Front Immunol; 2021; 12():713631. PubMed ID: 34512636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.
    Köhler N; Zeiser R
    Front Immunol; 2018; 9():3179. PubMed ID: 30705680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFAIP8 Deficiency Exacerbates Acute Graft Versus Host Disease in a Murine Model of Allogeneic Hematopoietic Cell Transplantation.
    Kumari R; Palaniyandi S; Strattan E; Huang T; Kohler K; Jabbour N; Dalland J; Du J; Kesler MV; Chen YH; Hildebrandt GC
    Transplantation; 2020 Mar; 104(3):500-510. PubMed ID: 31634333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Disruption of gut immune system caused by damage of intestinal stem cells and their niche in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.].
    Hayase E; Teshima T
    Clin Calcium; 2017; 27(6):829-833. PubMed ID: 28536321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Graft-versus-Host Disease: Novel Biological Insights.
    Teshima T; Reddy P; Zeiser R
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):11-6. PubMed ID: 26453971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.
    Joly AL; Deepti A; Seignez A; Goloudina A; Hebrard S; Schmitt E; Richaud S; Fourmaux E; Hammann A; Collura A; Svrcek M; Jego G; Robinet E; Solary E; Demidov O; Kohli E; Garrido C
    Oncogene; 2016 Jun; 35(22):2842-51. PubMed ID: 26364610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice.
    Buchele V; Büttner-Herold M; Vogler T; Neurath MF; Hildner K
    J Vis Exp; 2019 Feb; (144):. PubMed ID: 30799849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
    Shono Y; Docampo MD; Peled JU; Perobelli SM; Velardi E; Tsai JJ; Slingerland AE; Smith OM; Young LF; Gupta J; Lieberman SR; Jay HV; Ahr KF; Porosnicu Rodriguez KA; Xu K; Calarfiore M; Poeck H; Caballero S; Devlin SM; Rapaport F; Dudakov JA; Hanash AM; Gyurkocza B; Murphy GF; Gomes C; Liu C; Moss EL; Falconer SB; Bhatt AS; Taur Y; Pamer EG; van den Brink MRM; Jenq RR
    Sci Transl Med; 2016 May; 8(339):339ra71. PubMed ID: 27194729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
    Kumari R; Palaniyandi S; Hildebrandt GC
    Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
    Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.
    Wang H; Asavaroengchai W; Yeap BY; Wang MG; Wang S; Sykes M; Yang YG
    Blood; 2009 Apr; 113(15):3612-9. PubMed ID: 19211507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.
    Ullrich E; Abendroth B; Rothamer J; Huber C; Büttner-Herold M; Buchele V; Vogler T; Longerich T; Zundler S; Völkl S; Beilhack A; Rose-John S; Wirtz S; Weber GF; Ghimire S; Kreutz M; Holler E; Mackensen A; Neurath MF; Hildner K
    J Clin Invest; 2018 Mar; 128(3):916-930. PubMed ID: 29376889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.